HUYA Bioscience International Grants an Exclusive License for HBI-8000 in Japan and Other Asian Countries to Eisai

Eisai to commercialize HUYA’s Product in Lymphoma and Develop New Indications in Solid Tumors

San Diego, CA, USA – February 1, 2016HUYA Bioscience International (HUYA) President, CEO, Executive Chairman & Founder Dr. Mireille Gillings announced that Eisai Co., Ltd. has acquired from HUYA an exclusive license agreement for HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore.

Read more